Fig 2: Comparison of the expression of (A) CCL18, (B) CXCL1, (C) C1D, (D) TM4SF1, (E) FXR1, and (F) ZNF573 in ovarian cancer and normal tissues in TCGA and GTEx databases

Fig 3: (A) ROC curves of serum CCL18 and CXCL1 antigens and C1D, FXR1, TM4SF1, and ZNF573 IgG autoantibodies for the diagnosis of ovarian cancer in single and combined detection models. (B) ROC curve of the serum antigen-antibody combined detection model and CA125 alone for diagnosis of ovarian cancer. (C) ROC curve of the serum antigen-antibody combined detection model for the diagnosis of ovarian cancer and other malignant tumors. (D) ROC curve of the serum antigen-antibody combined detection model and CA125 alone for diagnosis of early-stage ovarian cancer

Fig 4: Violin image of immune cell infiltration. (A) Violin image of immune cell infiltration in the CCL18 group. (B) Violin image of immune cell infiltration in the TM4SF1 group

Fig 5: (A) Detection flow chart of the Flow Fluorescence Technology. (B) A dose-response standard curve of serum CCL18 and CXCL1 antigens detection. (C) A dose-response standard curve of C1D, TM4SF1, FXR1, and ZNF573 IgG autoantibodies detection